Overview

Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.

Phase:

Phase 4

Details

Lead Sponsor:

Toronto Rehabilitation Institute

Collaborator:

Ontario Neurotrauma Foundation

Treatments:

Bromides
Darifenacin
Oxybutynin
Trospium chloride